Biomarkers for detecting and predicting macular neovascularization in age-related macular degeneration using optical coherence tomography angiography: a systematic review.

Photodiagnosis Photodyn TherSep 4, 2026 (epub)
Clinical ResearchOphthalmology

Parva Pourbagherkhah, Hemn Baghban Jaldian

✦ AI-curated · Sources linked

In 30 seconds

This systematic review assessed the effectiveness of optical coherence tomography angiography (OCTA)-derived biomarkers in detecting and predicting macular neovascularization (MNV) in age-related macular degeneration (ARMD). The review included 11 studies with 642 eyes, highlighting strong associations between key biomarkers and disease activity. Notably, vascular density and MNV area were identified as significant indicators.

Key findings

  • Key OCTA biomarkers included vascular density, MNV area, total vessel length, and choroidal vascularity index.
  • The review included 11 studies with a total of 642 eyes.
  • Strong associations were found between OCTA biomarkers and disease activity and progression.

Why it matters

Understanding OCTA-derived biomarkers can enhance the ability to detect and monitor MNV in ARMD, potentially leading to improved patient outcomes through earlier diagnosis and tailored treatment approaches.

Source

PubMed · PMID 42697260

Published in Photodiagnosis Photodyn Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.